CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
High ImpactOriginal article

AstraZeneca sinks on unexpected heart drug trial failure

Phase 3negativeNegative
AI Analysis

Summary

AstraZeneca and Ionis Pharmaceuticals' heart disease treatment unexpectedly failed in a late-stage trial, causing AstraZeneca's share price to drop significantly.

Clinical Trial Data

Phase

3

Primary Endpoint

Not Met

Outcome Details

late-stage trial failure

Importance:8/10
Sentiment:
-0.90
Phase_3_failureheart_diseaseantisense_drugpartnershipstock_decline
Related Companies

Read the original article

Published by Endpoints News on July 9, 2026 7:58 AM

Read Original